Back to Search Start Over

PARP Inhibitors for Cancer Therapy.

Authors :
Lin KY
Kraus WL
Source :
Cell [Cell] 2017 Apr 06; Vol. 169 (2), pp. 183.
Publication Year :
2017

Abstract

Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.<br /> (Copyright © 2017. Published by Elsevier Inc.)

Subjects

Subjects :
BRCA1 Protein genetics
BRCA2 Protein genetics
Drug Approval
Female
Humans
Mutation
Ovarian Neoplasms genetics
Antineoplastic Agents therapeutic use
Indoles therapeutic use
Ovarian Neoplasms drug therapy
Poly(ADP-ribose) Polymerase Inhibitors therapeutic use

Details

Language :
English
ISSN :
1097-4172
Volume :
169
Issue :
2
Database :
MEDLINE
Journal :
Cell
Publication Type :
Academic Journal
Accession number :
28388401
Full Text :
https://doi.org/10.1016/j.cell.2017.03.034
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details